14results about "Colony-stimulating factor" patented technology

This invention provides a side-chain coupled compound of a cell-binding molecule having a branched linker and an amanita toxin compound. [Solution] A side-chain conjugated compound of formula (I), TIFF2026097851000286.tif25170 In one embodiment, a side-chain conjugated compound is provided, in which T is a cell-binding agent / molecule, W is a C1-C18 extension unit, and D is an amanita toxin, or an isotope of a chemical element, or a pharmaceutically acceptable salt, hydrate, or hydrated salt; or a polymorphic crystal; or an optical isomer, racemate, diastereomer, or enantiomer thereof.

The invention relates to single chain polypeptides having IL-10 and CSF1 activities and to their use in therapy.

A genetically-modified, immunodeficient mouse is provided along with methods of use, wherein the mouse includes (a) a nucleotide sequence encoding human stem cell factor (hSCF); (b) a nucleotide sequence encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF); (c) a nucleotide sequence encoding human interleukin-3 (hIL-3); and (d) a nucleotide sequence encoding human colony-stimulating factor 1 (hCSFl), wherein each of the nucleotide sequences is operably linked to a promoter, and wherein the genetically-modified, immunodeficient mouse expresses hSCF, hGM-CSF, hIL-3, and hCSFl, wherein the genetically-modified, immunodeficient mouse allows engraftment of human hematopoietic stem cells along with engraftment of human-patient derived tumor xenografts and / or human tumor cell lines to enable in vivo investigation of the interactions between the human immune system and human cancer.

A method for producing professional antigen-presenting cells and professional antigen-presenting cells are provided. [Solution] We provide a method for producing professional antigen-presenting cells, which includes obtaining proliferative myeloid cells (pMCs) by expressing c-MYC or the like in myeloid cells (MCs) differentiated from pluripotent stem cells, and obtaining professional antigen-presenting cells (pAPCs) by expressing GM-CSF and / or M-CSF in the pMCs, as well as human professional antigen-presenting cells produced by this method.

This specification describes immunogenic compositions comprising tumor cells expressing a fusokine containing GM-CSF linked to IL-7 by a peptide linker. Also described are pharmaceutical compositions and methods for treating patients with glioblastoma using tumor cells expressing a fusokine containing GM-CSF linked to IL-7 by a peptide linker.

A method of identifying anti-tumor activity of a test substance is provided along with a genetically-modified, immunodeficient mouse and methods of use, wherein the genetically-modified, immunodeficient mouse enables in vivo investigation of the interactions between the human immune system and human cancer.

An immunoresponsive cell, such as a T-cell expressing(i) a second generation chimeric antigen receptor comprising:(a) a signalling region;(b) a co-stimulatory signalling region;(c) a transmembrane domain; and(d) a binding element that specifically interacts with a first epitope on a target antigen; and(ii) a chimeric costimulatory receptor comprising(e) a co-stimulatory signalling region which is different to that of (b);(f) a transmembrane domain; andg) a binding element that specifically interacts with a second epitope on a target antigen.This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

In various embodiments, the present disclosure provides non-human animals comprising human immune cell transplantation and / or a functional human immune system. In various embodiments, the disclosure also provides methods of making the non-human animal. In various embodiments, the disclosure also provides methods of determining the immunogenicity of an antigen or an immunogenic fragment thereof or an antigen therapy and / or identifying an agent that modulates an immune response.

Genetically engineered progenitor cells and methods of using the same are disclosed herein. Genetically engineered cells differentiated from the genetically engineered progenitor cells of the present disclosure are also disclosed herein. Also disclosed herein is a method of treating a condition in a subject by administering the genetically engineered progenitor cells of the present disclosure or the genetically engineered cells differentiated from the genetically engineered progenitor cells.

Compositions and methods for modifying granulocyte-macrophage colony-stimulating factor (GM-CSF) as described. Non-naturally occurring cell engineered for production of GM-CSF with an altered glycosylation pattern comprising an expression vector having the CSF2 gene, and one or more knockout genes selected from the group consisting of MGAT5, ST3GAL3, ST3GAL4, ST3GAL6, B3GNT2, SPPL3, MGAT4A, and MGAT4B. In some embodiments, the cell additionally comprises a knock-in gene consisting of HST6GAL1.

The present invention provides: an oncolytic virus such as a conditionally replicating adenovirus carrying the CXCL10 gene; the oncolytic virus additionally carrying the IL-2 gene and / or the GM-CSF gene on the same viral genome; a combination of the oncolytic virus and a separate oncolytic virus carrying the IL-2 gene and / or the GM-CSF gene; and a cancer treatment agent comprising any of the aforementioned oncolytic viruses or a combination thereof as an active ingredient.

The disclosure provides, in various embodiments, non-human animals that comprise a human immune cell engraftment and / or functional human immune system. The disclosure also provides, in various embodiments, methods of generating said non-human animals. The disclosure also provides, in various embodiments, methods of determining immunogenicity of antigens or an immunogenic fragment thereof or antigenic therapies and / or identifying agents that modulate immune response.

The present invention relates to single chain polypeptides having IL-10 activity and CSF1 activity and their use in therapy.

Conjugates of a CSF-1 moiety and one or more water soluble polymers are provided. Typically, the water soluble polymer is a poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising conjugates, methods of making conjugates, methods of using the conjugates or compositions in therapeutic treatments, methods of administering conjugates or compositions comprising the conjugates to a patient, and kits comprising conjugates.